201 results
Page 5 of 11
424B5
e4f41kc
2 Feb 21
Prospectus supplement for primary offering
4:29pm
8-K
EX-99.1
nv3atfcs
29 Dec 20
Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
7:29am
8-K
EX-99.1
rte90z939jshat q17y
13 Nov 20
Moleculin Biotech, Inc. Reports Financial Results
7:29am
424B5
5v4 wx3qb7km
12 Nov 20
Prospectus supplement for primary offering
4:31pm
8-K
EX-99.1
bk70ak b52wm5pg
29 Oct 20
Moleculin Announces Additional Collaboration on Drug Candidate Targeting COVID-19
7:29am
8-K
29mf7hf4qtc7
21 Oct 20
Moleculin Announces Independent Study Validates Annamycin’s Ability to Target Lung Localized Tumors, Further Supporting IND
7:29am
8-K
EX-99.1
rww17dd
21 Oct 20
Moleculin Announces Independent Study Validates Annamycin’s Ability to Target Lung Localized Tumors, Further Supporting IND
7:29am
8-K
syqq9aynk xor0
7 Oct 20
Departure of Directors or Certain Officers
4:35pm
8-K
EX-99.1
1fvujvl304in1u
29 Sep 20
Moleculin Announces Discovery of Significant In Vitro Activity Against COVID-19 Virus for New
7:30am
8-K
EX-99.1
4k2ovlhj
14 Sep 20
Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122
4:30pm
8-K
e91q 7tmi462rn
26 Aug 20
Departure of Directors or Certain Officers
4:12pm
S-8
EX-4.4
yibfx3vru8va5k
21 Aug 20
Registration of securities for employees
4:31pm
S-8
EX-23.1
ngqv8z92zaid9
21 Aug 20
Registration of securities for employees
4:31pm
8-K
EX-99.1
3k8utpye3odfcjc
12 Aug 20
Results of Operations and Financial Condition
7:32am
8-K
u6rqbgf5rkjqoimky5v
21 Jul 20
Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus
8:41am
8-K
EX-99.1
elduaduci gfrgy3oa9k
21 Jul 20
Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus
8:41am
8-K
EX-1.1
flcx 9ri53in
17 Jul 20
Entry into a Material Definitive Agreement
5:19pm